Dmitry Shmerkovich, DO
Neurology · Brooklyn, NYNPI 1043486285
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Eisai Inc. at 35.5% of the total. Reporting peaked in 2019 at $1,189 and has fallen 82.6% since, to $207 in 2025.
Across 162 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1K
- UCB, Inc.$476
- AbbVie$343
- Genentech USA, Inc.$139
- Biogen$115
- Otsuka America Pharmaceutical, Inc.$114
- plus $962 from 21 others
What the payments were for
- Food & beverage$3,333100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 31 | $1,184 |
| UCB, Inc. | 39 | $476 |
| AbbVie(2 entities) | 14 | $343 |
| Genentech USA, Inc. | 10 | $139 |
| Biogen | 7 | $115 |
| Otsuka America Pharmaceutical, Inc. | 7 | $114 |
| Amgen | 5 | $99 |
| Argenx US, Inc. | 4 | $91 |
| Bristol Myers Squibb | 6 | $83 |
| Neurelis, Inc. | 3 | $72 |
| Sunovion Pharmaceuticals Inc. | 4 | $72 |
| Supernus Pharmaceuticals, Inc. | 4 | $69 |
| AstraZeneca | 4 | $65 |
| Sanofi | 3 | $59 |
| Vertical Pharmaceuticals, LLC | 3 | $52 |
| Greenwich Biosciences, Inc. | 3 | $52 |
| Livanova USA, Inc. | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Grifols USA, LLC | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$625
How this compares
$3,333 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 30 | $29,520 |
| FycompaPerampanel | 26 | $29,409 |
| BriviactBrivaracetam | 20 | $26,479 |
| Oxtellar XrOxcarbazepine | 26 | $24,044 |
| FingolimodFingolimod Hcl | 11 | $17,749 |
| OngentysOpicapone | 22 | $13,737 |
| Rufinamide | 17 | $9,483 |
| Clobazam | 57 | $4,944 |
| Levetiracetam | 115 | $4,115 |
| Lacosamide | 19 | $1,977 |
| Pregabalin | 29 | $1,907 |
| Levetiracetam ErLevetiracetam | 27 | $1,473 |
| Donepezil Hcl | 113 | $1,073 |
| Diazepam | 12 | $946 |
| Gabapentin | 96 | $941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $33 | $29,52030 claims |
| Eisai Inc.Fycompa | $1,184 | $29,40926 claims |
| UCB, Inc.Briviact | $476 | $26,47920 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $69 | $24,04426 claims |
| Neurocrine Biosciences, Inc.Ongentys | $20 | $13,73722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.
Other neurology in Brooklyn
- Idan SharonBrooklyn$2.1M
- Karen Blitz ShabbirBrooklyn$220K
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.